Stock Valuation: Urovant Sciences (NASDAQ: UROV)
Urovant Sciences is part of the biotechnology industry and trades as part of the healthcare sector.
Previous Intraday Performance:
The UROV shares had a previous change of -6.10% which opened at 8.00 and closed at 7.55. It moved to an intraday high of 8.42 and a low of 7.50.
SeekingAlpha: Urovant Sciences Limited (UROV) CEO Keith Katkin on Q4 2018 Results – Earnings Call Transcript
Historical Performance:
Over the last five trading days, UROV shares returned -4.31% and in the past 30 trading days it returned -5.63%. Over three months, it changed -42.93%. In one year it has changed -35.19% and within that year its 52 week high was 14.49 and its 52 week low was 4.06. UROV stock is 86.19% above its 52 week low.
Our calculations result in a 200 day moving average of 9.31 and a 50 day moving average of 8.18. Right now, UROV stock is trading -18.86% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Urovant Sciences Limited (UROV) CEO Keith Katkin on Q4 2018 Results – Earnings Call Transcript
Liquidity:
The company has a market cap of $228.9m with 30.3m shares outstanding and a float of 30.3m shares. Trading volume was 892,243 shares and has experienced an average volume of 70,049 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Urovant Sciences was -1.36 which ended on 31st of March 2018.
Below was the last reported quarterly diluted earnings per share:
| 4th | Qtr 2018 | Reported 06-13-2019: | -0.87 |
|---|---|---|---|
| 3rd | Qtr 2018 | Reported 02-13-2019: | -1.23 |
| 2nd | Qtr 2018 | Reported 11-12-2018: | -1.04 |
| 1st | Qtr 2018 | -1.24 | |
| 4th | Qtr 2017 | 0.00 |
Base on our calculations, the intrinsic value per share is 25.50, which means it might be undervalued and has a margin of safety of 70.39%.
The long-term trend of the EPS is a vital number as it helps understand the future potential of Urovant Sciences.
Indicators Also to Watch:
Based on the latest filings, there is 30.40% of institutional ownership.
The beta was calculated to be 1.66.
SeekingAlpha: Notes From The Road: An Equity Investor’s Lens On China
Fundamental Numbers:
Based on last reported financials, the company’s return on assets is -90.40% and price-to-book is 2.39.
Company Score Card:
Results are out of six:
3 : Growth Expectations Result
4 : Financial Safety Result
0 : Past Performance Result
3 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related
